Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 2/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7119259 | 0.80 | HRH3 (0.35) | HRH1HRH3DRD2KDM4EDRD4 | |
| SCHEMBL7125210 | 0.79 | HRH3 (0.32) | HRH1HRH3DRD2DRD3 | |
| SCHEMBL7128107 | 0.77 | CYP3A4 (0.39) | HRH1HRH3DRD2DRD3 | |
| SCHEMBL4877091 | 0.77 | HTR1A (0.35) | HTR7HRH3DRD2DRD3 | |
| SCHEMBL4871961 | 0.77 | SLC6A2 (0.34) | DRD2MAPTTSHRDRD4DRD3 | |
| SCHEMBL4877185 | 0.77 | SLC6A2 (0.34) | HRH3DRD2MAPTDRD3 | |
| SCHEMBL7127138 | 0.76 | HTR1A (0.44) | HTR7HRH3DRD2DRD4DRD3 | |
| SCHEMBL7128136 | 0.76 | ALDH1A1 (0.42) | HTR7DRD2KDM4E | |
| SCHEMBL6175964 | 0.75 | KDM4E (0.36) | KDM4ELMNAMAPTHPGDTSHR | |
| SCHEMBL5364670 | 0.75 | DRD2 (0.55) | HTR7HRH1HRH3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393845-B2 | Heteroaryl derivates, their preparation and use | H. LUNDBECK A/S (DK) | 2008-07-01 | — | — | US | claimed |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | claimed |
| EP-1399438-B1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2005-12-07 | — | — | EP | claimed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | claimed |
| EP-1399438-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2004-03-24 | — | — | EP | claimed |
| WO-2003002556-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2003-01-09 | — | — | WO | claimed |
| US-7393845-B2 | Heteroaryl derivates, their preparation and use | H. LUNDBECK A/S (DK) | 2008-07-01 | — | — | US | disclosed |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | disclosed |
| EP-1399438-B1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2005-12-07 | — | — | EP | disclosed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | disclosed |
| EP-1399438-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002556-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR1A | HTR7 65/4885HRH1 1505/4885HRH3 1115/4885 |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR2C | HTR7 51/4885HRH1 1734/4885HRH3 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.